BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32072159)

  • 1. Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology.
    Vogel T; Wendler J; Frank-Raue K; Kreissl MC; Spitzweg C; Fassnacht M; Raue F; Kroiss M
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32072159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
    Xu JY; Murphy WA; Milton DR; Jimenez C; Rao SN; Habra MA; Waguespack SG; Dadu R; Gagel RF; Ying AK; Cabanillas ME; Weitzman SP; Busaidy NL; Sellin RV; Grubbs E; Sherman SI; Hu MI
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4871-4877. PubMed ID: 27662441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.
    Mazziotti G; Formenti AM; Panarotto MB; Arvat E; Chiti A; Cuocolo A; Dottorini ME; Durante C; Agate L; Filetti S; Felicetti F; Filice A; Pace L; Pellegrino T; Rodari M; Salvatori M; Tranfaglia C; Versari A; Viola D; Frara S; Berruti A; Giustina A; Giubbini R
    Endocrine; 2018 Jan; 59(1):90-101. PubMed ID: 29110129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
    Tsuda Y; Nakagawa T; Shinoda Y; Kanatani A; Kawai T; Taguchi S; Yamada Y; Sawada R; Kume H; Homma Y; Tanaka S; Kawano H
    Int J Clin Oncol; 2017 Jun; 22(3):548-553. PubMed ID: 28044212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
    Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.
    Choksi P; Papaleontiou M; Guo C; Worden F; Banerjee M; Haymart M
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1254-1260. PubMed ID: 28324052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
    Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
    J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of bone metastases from head and neck squamous cell carcinoma.
    Suzuki A; Kashiwagi N; Doi H; Ishii K; Doi K; Kitano M; Kozuka T; Hyodo T; Tsurusaki M; Yagyu Y; Nakanishi K
    Auris Nasus Larynx; 2020 Apr; 47(2):262-267. PubMed ID: 31445714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
    Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
    Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
    Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
    Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
    [No Abstract]   [Full Text] [Related]  

  • 14. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer.
    Ueda CE; Duarte PS; de Castroneves LA; Flávio J; Marin G; Sado HN; Sapienza MT; Hoff AO; Buchpiguel CA
    Nucl Med Commun; 2020 May; 41(5):469-476. PubMed ID: 32187160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
    Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
    Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characteristics, metastasis-free survival, and skeletal-related events in 628 patients with skeletal metastases in a tertiary orthopedic and trauma center.
    Herget G; Saravi B; Schwarzkopf E; Wigand M; Südkamp N; Schmal H; Uhl M; Lang G
    World J Surg Oncol; 2021 Feb; 19(1):62. PubMed ID: 33632256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.
    Nervo A; Ragni A; Retta F; Gallo M; Piovesan A; Liberini V; Gatti M; Ricardi U; Deandreis D; Arvat E
    J Endocrinol Invest; 2021 Mar; 44(3):403-419. PubMed ID: 32743746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence and clinical impact of bone metastases in non-small cell lung cancer.
    Kuchuk M; Kuchuk I; Sabri E; Hutton B; Clemons M; Wheatley-Price P
    Lung Cancer; 2015 Aug; 89(2):197-202. PubMed ID: 26003503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
    Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
    Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance.
    Scharf M; Petry V; Daniel H; Rinke A; Gress TM
    Neuroendocrinology; 2018; 106(1):30-37. PubMed ID: 28152537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.